A PYMNTS Company

Teva-Cephalon final order approved, resolving FTC concerns with three generics

By  |  July 3, 2012

The Federal Trade Commission has approved an amended final order resolving competition concerns with Teva’s proposed acquisition of Cephalon. The approved final order comes after a public consultation. The transaction affects the generics market for three drugs. Teva will have to sell the rights and assets related to a drug used to treat cancer pain (transmucosal fentanyl citrate lozenges) and a generic muscle relaxant (extended release cyclobenzaprine hydrochloride). These two drugs will be sold to Par Pharmaceuticals, Inc. Teva is also required to enter into a supply agreement allowing Par to sell a generic version of Provigil, which is used to treat narcolepsy and other sleep disorders, in 2012.

Full content: FTC Press Release

 

Related content: Reverse Payment Settlements: Presumptively Bad or Usually Acceptable?

 

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.